JP2005535691A5 - - Google Patents

Download PDF

Info

Publication number
JP2005535691A5
JP2005535691A5 JP2004526013A JP2004526013A JP2005535691A5 JP 2005535691 A5 JP2005535691 A5 JP 2005535691A5 JP 2004526013 A JP2004526013 A JP 2004526013A JP 2004526013 A JP2004526013 A JP 2004526013A JP 2005535691 A5 JP2005535691 A5 JP 2005535691A5
Authority
JP
Japan
Prior art keywords
preparation
compound
acetate
implant
formulated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004526013A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005535691A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/020154 external-priority patent/WO2004012742A1/en
Publication of JP2005535691A publication Critical patent/JP2005535691A/ja
Publication of JP2005535691A5 publication Critical patent/JP2005535691A5/ja
Pending legal-status Critical Current

Links

JP2004526013A 2002-08-05 2003-06-26 加齢性黄斑変性を有する患者における視力の保護のための酢酸アネコルタブの使用 Pending JP2005535691A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40122002P 2002-08-05 2002-08-05
PCT/US2003/020154 WO2004012742A1 (en) 2002-08-05 2003-06-26 Use of anecortave acetate for the protection of visual acuity in patients with age related macular degeneration

Publications (2)

Publication Number Publication Date
JP2005535691A JP2005535691A (ja) 2005-11-24
JP2005535691A5 true JP2005535691A5 (https=) 2006-03-23

Family

ID=31495940

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004526013A Pending JP2005535691A (ja) 2002-08-05 2003-06-26 加齢性黄斑変性を有する患者における視力の保護のための酢酸アネコルタブの使用

Country Status (17)

Country Link
US (2) US20040127472A1 (https=)
EP (1) EP1539182A4 (https=)
JP (1) JP2005535691A (https=)
KR (1) KR20050026510A (https=)
CN (1) CN1674913A (https=)
AR (1) AR040599A1 (https=)
AU (1) AU2003281817A1 (https=)
BR (1) BR0313546A (https=)
CA (1) CA2494211A1 (https=)
DE (1) DE03742226T1 (https=)
ES (1) ES2244361T1 (https=)
MX (1) MXPA05000773A (https=)
PL (1) PL375024A1 (https=)
RU (1) RU2322239C2 (https=)
TW (1) TW200410699A (https=)
WO (1) WO2004012742A1 (https=)
ZA (1) ZA200500731B (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040127472A1 (en) * 2002-08-05 2004-07-01 Jerdan Janice A. Use of anecortave acetate for the protection of visual acuity in patients with age related macular degeneration
MXPA05008396A (es) * 2003-02-20 2006-03-30 Alcon Inc Formulaciones de glucocorticoides para tratar angiogenesis ocular patologica.
AU2004249256A1 (en) * 2003-06-20 2004-12-29 Alcon, Inc. Treatment of AMD with combination of ingredients
CA2539023A1 (en) * 2003-09-23 2005-04-14 Alcon Inc. Triamcinolone acetonide and anecortave acetate formulations for injection
US7257366B2 (en) * 2003-11-26 2007-08-14 Osmosis Llc System and method for teaching a new language
WO2005110374A1 (en) * 2004-04-30 2005-11-24 Allergan, Inc. Intraocular drug delivery systems containing a therapeutic component, a cyclodextrin, and a polymeric component
US20060182783A1 (en) * 2004-04-30 2006-08-17 Allergan, Inc. Sustained release intraocular drug delivery systems
US20070059336A1 (en) * 2004-04-30 2007-03-15 Allergan, Inc. Anti-angiogenic sustained release intraocular implants and related methods
US7261529B2 (en) * 2005-09-07 2007-08-28 Southwest Research Institute Apparatus for preparing biodegradable microparticle formulations containing pharmaceutically active agents
US7758778B2 (en) * 2005-09-07 2010-07-20 Southwest Research Institute Methods for preparing biodegradable microparticle formulations containing pharmaceutically active agents
US9693967B2 (en) * 2005-09-07 2017-07-04 Southwest Research Institute Biodegradable microparticle pharmaceutical formulations exhibiting improved released rates
US20070134244A1 (en) * 2005-10-14 2007-06-14 Alcon, Inc. Combination treatment for pathologic ocular angiogenesis
MX2009006146A (es) * 2006-12-18 2009-06-19 Alcon Res Ltd Dispositivos y metodos para la administracion de farmacos oftalmicos.
CN101759741B (zh) * 2008-11-06 2013-01-09 天津金耀集团有限公司 一种化合物及其在制备治疗血管新生的药物中的应用
CN101923856B (zh) 2009-06-12 2012-06-06 华为技术有限公司 语音识别训练处理、控制方法及装置
US20150037422A1 (en) * 2012-02-22 2015-02-05 Trustees Of Tufts College Compositions and methods for ocular delivery of a therapeutic agent
RU2489146C1 (ru) * 2012-07-11 2013-08-10 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт глазных болезней" Российской академии медицинских наук (ФГБУ "НИИГБ" РАМН) Способ лечения "сухой" формы возрастной макулярной дегенерации

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4876250A (en) * 1988-10-31 1989-10-24 Alcon Laboratories, Inc. Methods for controlling ocular hypertension with angiostatic steroids
RU2051651C1 (ru) * 1988-07-07 1996-01-10 Институт химии поверхности АН Украины Основа для глазных капель
US5371078A (en) * 1988-10-31 1994-12-06 Alcon Laboratories, Inc. Angiostatic steroids and methods and compositions for controlling ocular hypertension
US5770592A (en) * 1991-11-22 1998-06-23 Alcon Laboratories, Inc. Prevention and treatment of ocular neovascularization using angiostatic steroids
US5679666A (en) * 1991-11-22 1997-10-21 Alcon Laboratories, Inc. Prevention and treatment of ocular neovascularization by treatment with angiostatic steroids
ATE283013T1 (de) * 1999-10-21 2004-12-15 Alcon Inc Medikamentenzuführvorrichtung
US6416777B1 (en) * 1999-10-21 2002-07-09 Alcon Universal Ltd. Ophthalmic drug delivery device
US20040127472A1 (en) * 2002-08-05 2004-07-01 Jerdan Janice A. Use of anecortave acetate for the protection of visual acuity in patients with age related macular degeneration
US20070134244A1 (en) * 2005-10-14 2007-06-14 Alcon, Inc. Combination treatment for pathologic ocular angiogenesis

Similar Documents

Publication Publication Date Title
JP2005535691A5 (https=)
Porst IC351 (tadalafil, Cialis): update on clinical experience
SG10202112466UA (en) Control of cellular redox levels
JP2009507838A5 (https=)
Hassan et al. Khat chewing and arterial blood pressure. A randomized controlled clinical trial of alpha-1 and selective beta-1 adrenoceptor blockade
EP2210606A3 (en) Compositions comprising immunomodulatory compounds for the treatment and management of myeloproliferative diseases
TW200816985A (en) Methods for buccal, lingual or sublingual dosing regimens of epinephrine for the treatment of allergic emergencies
Alpsoy New Evidence‐Based Treatment Approach in Behçet′ s Disease
TW200815410A (en) Compositions and methods for treating, controlling, reducing, or ameliorating infections and sequelae thereof
JP2020505432A5 (https=)
RU2005106234A (ru) Применение ацетата анекортава для защиты остроты зрения пациентов с возрастной дегенерацией желтого пятна
JP2020500864A5 (https=)
JP2004537500A5 (https=)
WO2004050025A3 (en) Combination of ibuprofen and oxycodone for acute pain relief
Doshay Five-year study of benztropine (Cogentin) methanesulfonate: outcome in three hundred two cases of paralysis agitans
CA2483002A1 (en) New pharmaceutical composition
TW201841635A (zh) 用於治療抑鬱症之組合物及方法
CA2474430A1 (en) A combination of a thrombolytic agent and levosimendan for the treatment of acute myocardial infarction
JP3792251B2 (ja) 手術後の悪心および嘔吐の治療のためのグラニセトロンの使用
Kallenberg et al. Once daily felodipine in patients with primary Raynaud's phenomenon
Harrison et al. Relevance of duration of transient ischaemic attacks in carotid territory.
CA2443235A1 (en) Pharmaceutical compositions comprising ascomycin
WO2004043336A3 (en) Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myeloproliferative diseases
EP4392033A1 (en) Combination of a nurr1 agonist with at least one of an aldosterone antagonist, an insulin modulator and a sulfonylurea
Heaton et al. The role of apomorphine SL in the treatment of male erectile dysfunction.